FundedIQ
Biotechnology

Tonix Pharmaceuticals: Funding, Investors & Team (Sep 2026)

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.

www.tonixpharma.com LinkedIn New York, United States 101-250 employees
Biopharma Biotechnology Medical Pharmaceutical B2B
Total raised
$92.9M
Rounds
7
Latest
Undisclosed round
Dec 2025

Tonix Pharmaceuticals has raised $92.9M across 7 funding rounds on record, the most recent an undisclosed round of $20.0M announced in Dec 2025.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Tonix Pharmaceuticals Company Profile and Key Stats

Total funding raised
$92.9M
across 7 rounds on record
Funding rounds on record
7
1 with no disclosed amount
Latest funding round
Undisclosed round
$20.0M in Dec 2025
Employees
101-250
reported band
Headquarters
New York, United States

Latest funding round on record: Dec 2025.

Tonix Pharmaceuticals Funding Rounds

Date
Round
Amount
Undisclosed round
$20.0M
Undisclosed round
Undisclosed
Undisclosed round
$4.0M
Undisclosed round
$4.4M
Undisclosed round
$30.0M
Undisclosed round
$4.5M
Post-IPO Equity
$30.0M

1 of 7 rounds was announced without a disclosed amount and is excluded from the total.

Tonix Pharmaceuticals raised $30.0M in a Post-IPO Equity announced in Jun 2022.

1.3 years later, an undisclosed round of $4.5M was announced in Sep 2023.

3 months later, an undisclosed round of $30.0M was announced in Dec 2023.

3 months later, an undisclosed round of $4.4M was announced in Mar 2024.

3 months later, an undisclosed round of $4.0M was announced in Jun 2024.

9 months later, an undisclosed round was announced in Mar 2025 with no disclosed amount.

9 months later, an undisclosed round of $20.0M was announced in Dec 2025.

Tonix Pharmaceuticals Founders and Leadership Team

Name
Role
Contact
Seth Lederman
Founder
Locked

Contact details for the Tonix Pharmaceuticals team: 1 of 1 has an email address on file.

Start 14-day free trial →

Tonix Pharmaceuticals Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M

Tonix Pharmaceuticals' latest round of $20.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Tonix Pharmaceuticals in Biotechnology and New York

Companies Similar to Tonix Pharmaceuticals

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Tonix Pharmaceuticals Funding FAQs

What does Tonix Pharmaceuticals do?

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.

How much funding has Tonix Pharmaceuticals raised?

Tonix Pharmaceuticals has raised $92.9M across 7 rounds on record. The most recent is an undisclosed round of $20.0M announced in Dec 2025.

When did Tonix Pharmaceuticals last raise funding?

Tonix Pharmaceuticals' most recent funding round on record is an undisclosed round of $20.0M, announced in Dec 2025.

Who founded Tonix Pharmaceuticals?

FundedIQ lists Seth Lederman (Founder) at Tonix Pharmaceuticals.

Where is Tonix Pharmaceuticals headquartered?

Tonix Pharmaceuticals is based in New York, United States.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals is in the 101-250 employee band.

How does Tonix Pharmaceuticals' funding compare to other Biotechnology startups?

Tonix Pharmaceuticals' latest round of $20.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Tonix Pharmaceuticals Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Tonix Pharmaceuticals is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.